Cord blood infusion trial aims to beat long COVID fatigue

NCT ID NCT07184385

Not yet recruiting Symptom relief Sponsor: StemCyte, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether a single infusion of human umbilical cord blood, called REGENECYTE, can reduce fatigue in people with Long COVID. Sixty adults with post-COVID condition will receive either the cord blood or a placebo (salt water) and be monitored for changes in fatigue and side effects. The study is double-blind and randomized, meaning neither participants nor doctors know who gets the real treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human umbilical cord blood (REGENECYTE)
What this could lead to: If it works, this could offer a new treatment to ease severe fatigue in people with Long COVID.
What could go wrong: This is a small early-stage trial with only 60 people, so results may not apply to everyone. The treatment is an infusion, which carries risks like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID POST COVID CONDITION POST COVID-19 CONDITION POST-COVID SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.